Not Specific Cytokines but B Symptoms or C Reactive Proteins wereRelated the Infusion Reactions in Rituximab Treated B Cell Non-HodgkinâÂÂsLymphoma

Purpose: The purpose of this study is to analyze the risk factor for infusion related reaction (IRR) due to the rituximab treatment in patients with B cell non-Hodgkin’s lymphoma. Methods: A retrospective analysis was conducted the newly diagnosed B cell non-Hodgkin’s lymphoma patients who have received rituximab contained chemotherapy. Several factors with cytokines in patients were calculated. A P value <0.05 is significant. Results: 18 patients were included in the analysis. Most of patients were diffuse large B cell lymphoma or follicular lymphoma. Six patients had a IRR. TNF-α, IL6, IL8, sIL-2R, pre-administration of prednisolone were not observed significant differences. B symptom, CRP, gender was showed the significant differences in this analysis (B symptom: P=0.0139, gender: P=0.014, CRP: P=0.0354). Conclusion: B symptom, CRP, and gender might be important risk factors of the occurrence of IRR. Specific cytokines were not correlation with the IRR. Careful observation for IRR during rituximab administration is necessary for B cell non-Hodgkin’s lymphoma with B symptoms, and CRP positive patients.